Analysis of multiple organ damage and clinical immunological characteristics in systemic lupus erythematosus patients with hematologic involvement

Liming Tan1✉, Yonglei Zhao2

1. Department of Clinical Laboratory, Second Affiliated Hospital of Nanchang University, Jiangxi Key Laboratory of Laboratory Medicine, Nanchang 330006, China.
2. Second Clinical Medical College, Nanchang University, Nanchang 330006, China.

✉ Corresponding author: Liming Tan, Department of Clinical Laboratory, Second Affiliated Hospital of Nanchang University, Jiangxi Key Laboratory of Laboratory Medicine, Nanchang 330006, China.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2020.06.02; Accepted: 2020.12.17; Published: 2021.05.01

Abstract

Objective: To investigate clinical immunological characteristics and imaging findings of multiple organ damage of systemic lupus erythematosus (SLE) patients with hematologic involvement.

Methods: SLE patients diagnosed in the Second Affiliated Hospital of Nanchang University from June 2015 to March 2019 were selected, including 93 SLE patients with hematologic involvement and 68 SLE patients without hematologic involvement. Immunological indicators such as autoantibodies, immunoglobulin G (IgG), complement 4 (C4) and imaging data of several organs were measured respectively. The results were statistically analyzed.

Results: SLE patients with hematologic involvement were more likely to have autoimmune hemolytic anemia (AIHA) (20.43%, P<0.05). The erythrocyte sedimentation rate (ESR) of SLE patients with hematologic involvement was 75.82 (±35.33) mm/h, IgG was 28.84 (±6.00) g/L and C4 was 0.073 (±0.031) g/L (P<0.05). The area under the curve (AUC) of IgG was the highest among the above indicators (P<0.01). The positive anti-RO-52 antibody (OR=15.926, P<0.05) was an independent risk factor for pulmonary inflammatory lesions in SLE patients with hematologic involvement.

Conclusion: Compared with the control group, abnormal immunological indicators and multiple organs damage are more obvious. Positive anti-RO-52 antibody may play an important role in the pathogenesis of pulmonary inflammation in SLE patients.

Key words: systemic lupus erythematosus, hematological involvement, immunological characteristics, imaging findings

Introduction

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects a variety of systems and organs and is more common in women. Studies have shown [1, 2] that the kidney is one of the most easily affected organs in SLE. In recent years, other organ and system damages of SLE patients have been gradually reported, such as blood system, nervous system damages and gastrointestinal dysfunction [3-5]. Studies have shown that some patients’ blood system has been injured to varying degrees, including thrombocytopenia, anemia, leukopenia and other clinical features, and combined with damage to vital organs such as liver, heart and lung [5, 6]. Enhanced immune system activity is one of the main manifestations of SLE, which are characterized by high gamma globulinemia, immune complex formation and activation of the complement system. The core of its pathogenesis is the highly specific reaction between autoantibodies and autoantigens. These reactions interact with each other in the blood system circulation in SLE patients, causing early damage of some organs. Clinical workers may miss these organ damage. This study analyzed imaging characteristics of hematologic abnormalities in
autoantibodies, immunoglobulin, complement, and organs (such as the heart and lungs) of SLE patients. According to these indicators, this study provides a reference basis for correctly determining the outcome of SLE clinically and adopting a more comprehensive and timely treatment regimen.

Methods

Patients

93 SLE patients with hematologic involvement and 68 SLE patients without hematologic involvement diagnosed in the second affiliated hospital of Nanchang university from June 2015 to March 2019 were selected. All patients met the standard (SLICC) formulated by SLE international cooperative clinic in 2012 [7]. Diagnostic criteria for abnormal hematologic manifestations include: leukopenia (whole blood leukocyte count < 4×10⁹/L); Autoimmune hemolytic anemia (AIHA) (1 hemoglobin level reaches anemia standard. 2 erythrocyte autoantibodies are detected. 3 at least one of the following: reticulocyte percentage > 4% or absolute value > 20×10⁹/L; combined globin <100 mg / L; total bilirubin ≥ 17.1 μ mol / L, with unbound bilirubin increased); thrombocytopenia (platelets <100×10⁹/L). All specimens were collected with the informed consent of the patients. The study was approved by the Ethics Committee of the Second Affiliated Hospital of Nanchang University.

Inclusion criteria

All participants met the following criteria: 1) signed informed consent, voluntary participation, 2) with clear diagnosis, complete clinical data and imaging data, 3) Any drugs that seriously affect the blood system, heart and lungs were not taken within three months of admission.

Exclusion criteria

Exclusion criteria were as follows: 1) patients with other autoimmune diseases; 2) patients with severe infectious diseases or other causes of hematological diseases within 3 months; 3) patients with malignant tumors; 4) pregnant or lactating patients; 5) lupus caused by drugs.

Instruments and methods

IgG, C3 and C4 were measured by Beckman Immage800 specific protein analysis system and associated detection reagent (Beckman, USA). Erythrocyte sedimentation rate (ESR) measured by Percil XC - 40 full-automatic dynamic blood sedimentation. Indirect immune fluorescense (IIF) was used to measure anti-nuclear antibody (ANA) and anti-double-stranded DNA (ds-DNA) antibody. The anti-nuclear antibody spectrum assay kit, EURO Blot Master II and linear immunoblot assay (LIA) were used to measure the anti-nuclear antibody spectrum. CT examination was used by GE 64-slice Light Speed VCT, (GE Healthcare), Philips 16-slice spiral CT (Philips Healthcare) and Siemens Somatom Definition Flash (Siemens Healthcare) for axial or coronal scanning of vital organs such as lungs and liver. Philips IE33 type and Philips IE elite type multifunctional color doppler ultrasound diagnostic instrument were used with a frequency of 1.0 ~ 5.0 mhz. The patients were placed in left lateral position and supine position to examine the heart, pericardium, liver and spleen. All operations were carried out in strict accordance with the instructions of each reagent and the quality management standard documents of the second affiliated hospital of Nanchang university.

Statistical analysis

Statistical analysis of the data was performed by SPSS program version 22. Continuous variables of normal distribution were expressed as mean ± standard deviation (x±s), and T-test was adopted for comparison between any two means. Continuous variables of non-normal distribution was described by M (P25, P75), Mann-Whitney U test was used for comparison between any two means. Chi-square test and Fisher’s exact test were used for categorical variables. A binary logistic regression model was used to analyze the independent risk factors for each organ injury. Receiver operating characteristics (ROC) analysis was performed, and the best cut-off value was determined. Area under the curve (AUC) was calculated. AUC=0.5~0.7 indicated low diagnostic accuracy. AUC=0.7~0.9 indicated a certain diagnostic accuracy. AUC > 0.9 indicated a high diagnostic accuracy. P<0.05 was considered statistically significant.

Results

Basic characteristics of SLE patients with and without hematologic involvement

Compared with SLE patients without hematologic involvement, SLE patients with hematologic involvement were more likely to have AIHA (P < 0.05) and accelerated ESR (P < 0.01). As shown in Table 1.

Immunological characteristics of SLE patients with hematologic involvement and SLE patients without hematologic involvement

Compared with SLE patients without hematologic involvement, SLE patients with hematologic involvement had higher IgG and quantitative anti-dsDNA antibodies than patients
without hematologic involvement. The levels of complement C3 and C4 in SLE patients with hematologic involvement were lower, (0.45±0.19g/L and 0.073±0.031 g/L) respectively (P<0.01). The positive rate of anti-SS-B and anti-AnuA was higher (P < 0.05). As shown in Table 2.

Table 1. Basic characteristics of the two groups of patients

|                      | SLE with hematologic involvement (N = 93) | SLE without hematologic involvement (N = 68) | P value |
|----------------------|------------------------------------------|---------------------------------------------|---------|
| Female               | 83 (89.25)                               | 62 (91.18)                                  | 0.686   |
| Age (years)          | 38.7±16.4                                | 40.8±14.4                                   | 0.434   |
| AIHA                 | 19 (20.43)                               | 6 (8.82)                                    | 0.045   |
| Leukopenia           | 12 (12.90)                               | 11 (16.17)                                  | 0.558   |
| Thrombocytopenia     | 38 (40.86)                               | 21 (30.88)                                  | 0.194   |
| ESR (mm/h)           | 73.82±35.33                              | 47.79±24.58                                 | 0.001   |

Note: T-test and Chi-square test were used. SLE, systemic lupus erythematosus; AIHA, autoimmune hemolytic anemia; ESR, erythrocyte sedimentation rate.

ROC curve analysis of ESR and immunological indicators

AUC (95% CI) was obtained according to ESR, dsDNA, IgG, C3 and C4, so as to evaluate the diagnostic value of these indicators in SLE patients with hematologic involvement. The results showed that the AUC of ESR, dsDNA, IgG, C3 and C4 were all greater than 0.7, and the AUC of IgG was 0.891 (P< 0.01), which proved that it has good diagnostic value for SLE hematological system involvement (Table 3 and Figure 1).

The imaging findings of lung, liver and other vital organs in the two groups

CT and ultrasonography showed that SLE patients with hematologic involvement were more likely to have pulmonary inflammatory lesions, hepatic cysts and splenomegaly (P<0.05). As shown in Table 4.

Table 2. Immunological characteristics of the two groups’ patients

|                      | SLE with hematologic involvement (N = 93) | SLE without hematologic involvement (N = 68) | P value |
|----------------------|------------------------------------------|---------------------------------------------|---------|
| C3 (g/L)             | 0.45±0.19                                | 0.65±0.21                                  | <0.001  |
| C4 (g/L)             | 0.073±0.029                              | 0.136±0.053                                | <0.001  |
| IgG (g/L)            | 28.84±6.60                               | 21.94±5.56                                 | <0.001  |
| Anti-dsDNA (IU/ml)   | 174.60 [87.61,643.80]                    | 36.28 [29.04,126.79]                       | <0.001  |
| ANA                  | 90 (96.77)                               | 66 (97.06)                                 | >0.999  |
| Anti-dsDNA           | 45 (48.39)                               | 32 (47.06)                                 | 0.868   |
| Anti-SS-A            | 54 (58.06)                               | 38 (55.88)                                 | 0.782   |
| Anti-SS-B            | 25 (26.88)                               | 9 (13.24)                                  | 0.036   |
| Anti-Ro-52           | 47 (50.54)                               | 30 (44.18)                                 | 0.421   |
| Anti-Sm              | 19 (20.43)                               | 16 (23.53)                                 | 0.638   |
| Anti-Histone         | 17 (18.28)                               | 14 (20.59)                                 | 0.714   |
| Anti-ANuA            | 56 (60.22)                               | 29 (42.65)                                 | 0.027   |
| Anti-Rib P           | 22 (23.66)                               | 18 (26.47)                                 | 0.683   |
| Anti-nRNP/Sm         | 23 (24.73)                               | 23 (33.82)                                 | 0.207   |
| Anti-CENP-B          | 5 (5.38)                                 | 3 (4.41)                                   | >0.999  |

Note: T-test, Chi-square test and Mann-Whitney U test were used. SLE, systemic lupus erythematosus; C3, Complement 3; C4, Complement 4; IgG, immunoglobulin G; ANA, anti-nuclear antibody; Anti-dsDNA, anti-double-stranded DNA; Anti-SS-A, anti-Sjogren’s syndrome antigen A; Anti-SS-B, anti-Sjogren’s syndrome antigen B; Anti-Sm, anti-Smith; Anti-Histone, anti-histone antibody; Anti-ANuA, anti-nucleosome antibodies; Anti-Rib P, anti-ribosomal antibody.

Binary Logistic regression analysis of pulmonary inflammatory lesions

To further investigate whether the imaging features of these organ lesions were related to autoantibodies, a multivariate binary logistic regression model was used in this study. Due to the word limit, only a few items are selected and listed in Table 5. The results showed that RO-52 antibody positive was an independent risk factor for pulmonary inflammatory lesions after exclusion of confounding factors (OR=15.926, P<0.05).

Discussion

SLE patients had diverse immunological characteristics and clinical manifestations. In previous studies, scholars mainly focused on LN, which is a kind of common and severe organ damage caused by SLE [2, 8]. In recent years, a number of studies have shown that an increasing number of systems and organs were involved in SLE besides kidney, including blood system, nervous system and gastrointestinal tract, which may be caused by the
formation of immune complex, complement system activation and specific autoantigen antibody reaction in SLE patients [4, 9, 10]. This study is the clinical data of patients with SLE blood system involvement. This retrospective analysis was conducted to explore the characteristics of blood system involvement in SLE patients and observe the relationship between blood system involvement and SLE Clinical indicators, laboratory indicators to guide clinical diagnosis and treatment.

Table 3. ROC curve analysis of ESR and immunological indicators

| Index        | AUC   | Standard error | P value | 95% confidence interval |
|--------------|-------|----------------|---------|-------------------------|
| ESR          | 0.726 | 0.057          | 0.01    | 0.615-0.873             |
| IgG          | 0.891 | 0.043          | <0.01   | 0.806-0.975             |
| C3           | 0.753 | 0.055          | <0.01   | 0.645-0.861             |
| C4           | 0.852 | 0.040          | <0.01   | 0.753-0.910             |
| Anti-dsDNA   | 0.826 | 0.064          | <0.01   | 0.701-0.952             |

Note: AUC, Area under the curve; ESR, erythrocyte sedimentation rate; IgG, immunoglobulin G; C3, Complement 3; C4, Complement 4; Anti-dsDNA, anti-double-stranded DNA.

Table 4. Imaging findings of important organ lesions in the two group

| Imaging findings             | SLE with hematologic involvement (N = 93) | SLE without hematologic involvement (N = 68) | P value |
|------------------------------|------------------------------------------|---------------------------------------------|---------|
| Chest/Lung                   |                                          |                                             |         |
| Inflammatory lesion          | 65 (69.89)                               | 35 (51.47)                                 | 0.017   |
| Small nodule                 | 7 (7.53)                                 | 3 (4.41)                                   | 0.632   |
| Stri t stove                 | 21 (22.58)                               | 9 (13.24)                                  | 0.133   |
| Solid change                 | 21 (22.58)                               | 14 (20.59)                                 | 0.762   |
| Lymphadenopathy              | 24 (25.81)                               | 12 (17.65)                                 | 0.220   |
| Pleural effusion             | 31 (33.30)                               | 20 (29.41)                                 | 0.597   |
| Liver/Spleen                 |                                          |                                             |         |
| Hepatic cyst                 | 28 (30.11)                               | 10 (14.71)                                 | 0.023   |
| Hepatic calcification        | 17 (18.28)                               | 7 (10.29)                                  | 0.160   |
| Fatty liver                  | 9 (9.68)                                 | 1 (1.47)                                   | 0.072   |
| Splenomegaly                 | 12 (12.90)                               | 3 (4.33)                                   | 0.045   |
| Heart                        |                                          |                                             |         |
| Valvular regurgitation       | 45 (48.39)                               | 26 (38.24)                                 | 0.200   |
| Left ventricular diastolic dysfunction | 30 (32.26) | 19 (27.94) | 0.557   |
| Pericardial effusion         | 24 (25.81)                               | 23 (33.82)                                 | 0.269   |

Note: Chi-square test and Fisher’s exact test were used.

Table 5. Binary Logistic regression analysis of pulmonary inflammatory lesions

| Indicators | β value | SE  | Wald   | P value | Exp(B) | 95% confidence interval |
|------------|---------|-----|--------|---------|--------|-------------------------|
| Anti-RO-52 | 2.768   | 1.117 | 6.140  | 0.013   | 15.926 | 1.784-142.21            |
| Anti-SS-A  | 1.015   | 0.058 | .920   | 0.337   | 2.759  | 0.347-21.946            |
| Anti-SS-B  | -1.531  | 1.142 | 1.798  | 0.180   | 0.180  | 0.023-2.027             |
| Anti-dsDNA | 0.002   | 0.001 | 2.467  | 0.116   | 1.002  | 1.000-1.004             |

Note: Anti-SS-A, anti-Sjoergen’s syndrome antigen A; Anti-SS-B, anti-Sjoergen’s syndrome antigen B; Anti-dsDNA, anti-double-stranded DNA.

The results showed that the gender and age distribution of the two groups were similar. The hematologic involvement in SLE patients is mainly characterized by AIHA, leukopenia, and thrombocytopenia, consistent with a retrospective analysis of Anum Fayyaz [6], which were common manifestations of hematologic lesions in SLE. SLE patients with hematologic involvement were more likely to have abnormal blood system manifestations. Compared with a study conducted by El, H.K. et al in a clinic in Cairo, Egypt [11], the probability of leukopenia in this study was lower, which may be caused by different geographical, ethnic and diagnostic levels. Then, ESR and immunological indicators of the patients were analyzed. Compared with SLE patients without hematologic involvement, patients with hematologic involvement had higher IgG and quantitative anti-dsDNA antibodies than patients without hematologic involvement. Compared with SLE patients without hematologic involvement, the levels of complement C3 and C4 in SLE patients with hematologic involvement were lower. Previous studies [12, 13] have shown that IgG, C3 and C4 can be used as indicators to monitor the active stage of SLE disease, and hematologic involvement in the clinical diagnostic guidelines of SLE disease was also classified as the performance of SLE disease activity. The results of this study were proved to be reliable. The ANA and ENAs were analyzed. The results of the autoantibody study in SLE patients were similar to the study by Feng, X. et al. [15] in Meizhou, Guangdong Province, China. And the positive rates anti-dsDNA antibody were also basically consistent. It was noteworthy that in the analysis of ENAs, the anti-SS-B antibody of SLE patients with hematologic involvement showed a higher positive rate of 26.88%, significantly higher than that of the other group (13.24%). In previous studies [16, 17], anti-ANuA antibodies were considered to be a specific antibody besides dsDNA in SLE patients with specificity of up to 90% and were associated with disease activity in SLE. It was consistent with this study. Anti-dsDNA antibody is one of the self-specific antibodies of SLE, the positive rate of which reached 48.39% in this study. In a study conducted by Gheita, T.A. et al. [18], anti-dsDNA antibody titers were associated with ESR, and dsDNA quantitative analysis was used in this study to make the correlation between the indicators more intuitive and accurate. Finally, AUC (95% CI) was obtained according to ESR, dsDNA, IgG, C3 and C4, so as to evaluate the diagnostic value of these indicators in SLE patients with hematologic involvement. The results showed that the AUC of IgG was 0.891, which proved that it has good diagnostic value for SLE hematological system involvement.

In addition, this study analyzed the imaging characteristics of organs in the two groups of patients. The imaging features of the lungs were mainly
inflammatory lesions, small nodules, consolidation and cord lesions. The positive rate of pneumonia lesions in SLE patients with hematologic involvement was 69.89%, which was higher than that of the other group (51.47%). The lungs involvement of SLE has been reported in the past [19-21], the probability of lung involvement is lower than the results in this study, which may be caused by smoking, treatment levels, individual immunity and other factors. The imaging features of the heart were mainly valvular regurgitation (mainly mitral, aortic, tricuspid), left ventricular diastolic dysfunction, pericardial effusion, although the difference between the two groups was not statistically significant, but both had a high positive rate which suggested that there may be damage to the heart in SLE patients in the early stages, especially the valve damage. In previous studies, it has been suggested that the heart of SLE patients is very vulnerable [22, 23], so it must be taken seriously. In addition, liver and spleen were also easily affected by SLE. The results showed that hepatic cysts, hepatic calcification, fatty liver and splenomegaly were common imaging findings in SLE patients, and SLE patients with hematologic involvement more likely had hepatic cysts and splenomegaly. As mentioned above, organ damage in SLE patients with hematologic involvement were very common, which may be caused by the specific antibodies and complement of SLE patients as blood circulated in various organs and eventually reacted and accumulated. A multivariate binary logistic regression model was used to investigate whether the imaging features of these organ lesions were related to autoantibodies in this study. The results showed that RO-52 antibody positive was an independent risk factor for pulmonary inflammatory lesions after exclusion of confounding factors. For SLE patients with positive RO-52 antibody, patients should be closely monitored and paid attention to the lungs of patients to reduce the incidence of lung inflammation and improve the prognosis of the disease. In the process of diagnosis and treatment, it was necessary to review and closely monitor the functions of vital organs such as liver and lung to prevent irreversible damage. In addition to multiple organ damage in patients caused by SLE disease itself, in the treatment of SLE disease, a large number of glucocorticoids and biological agents need to be used for patients, which may also cause chronic failure of many organs of patients [24, 25]. Therefore, attention must be paid to the monitoring and treatment of multiple organ functions in SLE patients.

In conclusion, it was proved that SLE patients with hematologic involvement were more likely to have abnormal immunological characteristics. Heart, lung and liver damage were more likely to occur in these patients. The positive anti-RO-52 antibody may promote the occurrence of pulmonary inflammation. It was suggested that the damage of various organs and systems in SLE patients should be diagnosed early to reduce the occurrence of systemic lupus erythematosus involving the blood system thereby improving the prognosis of patients.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Ho R C, Thiagbu C, Ong H, et al. A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus[J]. Autoimmun Rev. 2016, 15(6):124-138.
2. Hevia A, Milani C, Lopez P, et al. Intestinal dysbiosis associated with systemic lupus erythematosus[J]. Micron. 2014, 5(6): 1514-1548.
3. Velo-García A, Castro S G, Isenberg D A. The diagnosis and management of the haematoLOGic manifestations of lupus[J]. Journal of Autoimmunity. 2016, 74: 139-160.
4. Fayyaz A, Igoe A, Kurien B T, et al. Haematological manifestations of lupus[J]. Lupus Science & Medicine. 2015, 2(1): e78.
5. Petri M, Orbai A M, Alarcon G S, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus[J]. Arthritis Rheum. 2012, 64(6): 2677-2686.
6. Freedman B I, Langefeld C D, Andringa K K, et al. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1[J]. Arthritis Rheumatol. 2014, 66(2): 390-396.
7. Hanly J G, O’Keeffe A G, Su L, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study[J]. Rheumatology. 2016, 55(2): 252-262.
8. Stock A D, Wen J, Putterman C. Neuropsychiatric Lupus, the Blood Brain Barrier, and the TWEAK/Fn14 Pathway[J]. Front Immunol. 2013, 4: 484.
9. Taraborelli M, Cavazana I, Martinazzi N, et al. Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years[J]. Lupus. 2017, 26(11):1197-1204.
10. El H K, Medhat B M, Abdel B N, et al. Characteristics of systemic lupus erythematosus in a sample of the Egyptian population: a retrospective cohort of 1109 patients from a single center[J]. Lupus. 2018, 27(6): 1030-1038.
11. Kao A H, Navratil J S, Ruffing M J, et al. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus[J]. Arthritis & Rheumatism. 2010, 62(3): 837-844.
12. Hestova M H, Stoyanova V S. Autoantibodies against complement components in systemic lupus erythematosus - role in the pathogenesis and clinical manifestations[J]. Lupus. 2017, 26(14): 1550-1555.
13. Feng X, Zou Y, Pan W, et al. Associations of clinical features and prognosis with age at disease onset in patients with systemic lupus erythematosus[J]. Lupus. 2013, 22(3): 327-334.
14. Su Y, Jia R L, Han L, et al. Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus[J]. Clin Immunol. 2007, 122(1): 115-120.
15. Bizzaro N, Villalta D, Giavarina D, et al. Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis[J]. Autoimmunity Reviews. 2012, 12(2): 97-106.
16. Gheita T A, Abaza N M, Hammam N, et al. Anti-dsDNA titre in female systemic lupus erythematosus patients: relation to disease manifestations, damage and antiphospholipid antibodies[J]. Lupus. 2018, 27(7): 1081-1087.
17. Allen D, Fischer A, Bshouty Z, et al. Evaluating systemic lupus erythematosus patients for lung involvement[J]. Lupus. 2012, 21(12): 1316-1325.
18. Deeb M, Tselios K, Gladman D D, et al. Shrinking lung syndrome in systemic lupus erythematosus: a single-centre experience[J]. Lupus. 2018, 27(3):365-371.
19. Haye S M, Caeiro F, Saurit V, et al. Pleuropulmonary involvement in patients with systemic lupus erythematosus from a Latin American inception cohort (GLADEL)[J]. Lupus. 2017, 26(13): 1368-1377.
20. Mohamed A A A, Hammam N, El Zohri M H, et al. Cardiac Manifestations in Systemic Lupus Erythematosus: Clinical Correlates of Subclinical Echocardiographic Features[J]. BioMed Research International. 2019, 2019: 1-8.
21. Bourné-Tessier J, Huynh T, Clarke A E, et al. Features associated with cardiac abnormalities in systemic lupus erythematosus[J]. Lupus. 2011, 20(14): 1518-1525.
22. Tarr T, Papp G, Nagy N, et al. Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus[J]. Clinical Rheumatology. 2017, 36(2): 327-333.
23. Samotij D, Reich A. Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review[J]. BioMed Research International. 2019, 2019: 1-17.
24. Tarr T, Papp G, Nagy N, et al. Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus[J]. Clinical Rheumatology. 2017, 36(2): 327-333.
25. Samotij D, Reich A. Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review[J]. BioMed Research International. 2019, 2019: 1-17.